Physician profile
Daniel Markley
NPI 1790981876
$530.94
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $65.75 · 2021: $71.64 · 2022: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $160.74 | 2019-2020 | |
| Philips North America LLC | $141.30 | 2022 | |
| Edwards Lifesciences Corporation | $56.65 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.26 | 2019-2020 | |
| Ekos Corporation | $37.00 | 2019 | |
| Genzyme Corporation | $29.25 | 2020-2021 | |
| Optinose US, INC. | $18.64 | 2022 | |
| Mylan Specialty L.P. | $16.00 | 2022 | |
| Pharming Healthcare, INC. | $14.75 | 2019 | |
| Grifols USA, LLC | $13.35 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Markley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.